Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma and Plasma Cell Neoplasm: early-phase trial registry
3 of 45 indexed Multiple Myeloma and Plasma Cell Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #323 of 28,707 conditions by registered trial count.
45 US clinical trials · 3 currently recruiting · #323 of 28,707 conditions by registered trial count
Multiple Myeloma and Plasma Cell Neoplasm: 45 US clinical trials tracked, 3 recruiting.
Multiple Myeloma and Plasma Cell Neoplasm is the subject of 45 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 6 of these trials.
Enrollment posture brief
Registry condition multiple-myeloma-and-plasma-cell-neoplasm
OPEN 3 | RECR 7% | LATE 8 | EARLY 31 | RANK #323 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Liver Disease (7% recruiting · 15 trials)
Multiple Myeloma and Plasma Cell Neoplasm lists 3 open slots (7% of 45 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma and Plasma Cell Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma and Plasma Cell Neoplasm is recruiting below its size-band peers.
3 of 45 indexed trials (6.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma and Plasma Cell Neoplasm trials is spread across many organizations.
Mayo Clinic accounts for 6 of 45 trials (13.3%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Multiple Myeloma and Plasma Cell Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 27 trials that report a genuine target (sentinel values excluded). 22 of those (81.5%) plan for fewer than 100 participants.
-
Multiple Myeloma and Plasma Cell Neoplasm research is mostly interventional.
42 interventional and 3 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
45 total, page 1 of 1
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137643
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137825
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
NCT00935090
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Mayo Clinic
NCT00661999
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
City of Hope Medical Center
NCT00964821
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT00003341
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
NCT00432458
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
NCT00609167
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT00478075
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
NCT00003398
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
National Cancer Institute (NCI)
NCT00003853
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
NCT00458822
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT00534118
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Oncotherapeutics
NCT00316940
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
NCT00564889
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
NCT00104923
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Abramson Cancer Center at Penn Medicine
NCT00568880
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
University of Miami
NCT00006021
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
Fox Chase Cancer Center
NCT00006013
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
Case Comprehensive Cancer Center
NCT00004072
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00301951
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
NCT00005092
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00304018
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Barbara Ann Karmanos Cancer Institute
NCT00258245
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Genta Incorporated
NCT00017602
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT00002502
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Northwestern University
NCT00004165
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
NCT00004232
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
NCT00002907
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
California Cancer Consortium
NCT00022607
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
NCT00064311
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
Northwestern University
NCT00004181
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00005804
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
NCT00046852
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University School of Medicine
NCT00003107
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00006098
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
NCT00006362
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT00014482
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00003395
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
NCT00006083
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00006042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 14 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Myeloma and Plasma Cell Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Myeloma and Plasma Cell Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Myeloma and Plasma Cell Neoplasm page
45 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Multiple Myeloma and Plasma Cell Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Multiple Myeloma and Plasma Cell Neoplasm trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Myeloma and Plasma Cell Neoplasm condition card totals 45 registered trials; most-linked intervention bortezomib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.